Parallax Volatility Advisers’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-15,000
Closed -$144K 2919
2022
Q3
$144K Buy
+15,000
New +$152K ﹤0.01% 2401
2018
Q2
Sell
-38,600
Closed -$427K 2196
2018
Q1
$427K Hold
38,600
﹤0.01% 1148
2017
Q4
$340K Buy
38,600
+37,500
+3,409% +$401K ﹤0.01% 1831
2017
Q3
$15K Hold
1,100
﹤0.01% 1722
2017
Q2
$16K Buy
+1,100
New +$21.2K ﹤0.01% 1946

Other funds holding CHRS

Parallax Volatility Advisers's CHRS Position: Q4 2022 in Review

Parallax Volatility Advisers sold out of Coherus Oncology (CHRS) in Q4 2022, closing a stake of 7,298 shares — an estimated $70K sold.

Parallax Volatility Advisers first reported a position in CHRS in Q2 2017 and held it in 5 quarters. The position peaked at $220K in Q4 2017. 161 funds tracked by Wall St. Rank hold CHRS as of Q4 2022.

  • Parallax Volatility Advisers reported no remaining Coherus Oncology position as of Q4 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 7,298 Coherus Oncology shares in Q4 2022, an estimated $70K.
  • Parallax Volatility Advisers first reported a position in Coherus Oncology in Q2 2017 and held it in 5 quarters.
  • Parallax Volatility Advisers's Coherus Oncology position peaked at $220K in Q4 2017.
  • 161 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2022.

Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.